Therapeutic and Economic Value of Everolimus Plus Exemestane for the Treatment of Postmenopausal Women with Hormone Receptor-Positive, Her2/Neu Negative Advanced Breast Cancer.
نویسندگان
چکیده
Cost-effectiveness of everolimus+exemestane as compared to fulvestrant was assessed in terms of the incremental cost per life year (LY) gained, from a Portuguese National Health Service (NHS) perspective. Next to main therapeutic drug costs, other healthcare costs included costs for medical visits, complementary diagnostic procedures, surgery, inpatient visits, additional therapy and end-of-life care. An annual 5% discount rate was applied to both costs and effectiveness.
منابع مشابه
Patients’ preferences and willingness-to-pay for postmenopausal hormone receptor-positive, HER2-negative advanced breast cancer treatments after failure of standard treatments
Patients' preferences increasingly play roles in cancer treatments. The objective of this study is to examine breast cancer patients' preferences and willingness-to-pay (WTP) for postmenopausal hormone receptor-positive, HER2-negative advanced breast cancer treatments after failure of standard treatments. Four attributes, i.e. progression free survival (PFS), anemia, pneumonitis, and cost, and ...
متن کاملNew directions in improving response to endocrine therapy cancer.
S6-01. Finn RS, Crown JP, Lang I, et al. The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/ TRIO-18): a randomised phase 2 study. Lancet Oncol. 2015;16(1):25-35. Turner NC, Ro J, André F, et al. Palbociclib in hormone-receptor-positive ...
متن کاملOverall survival and progression-free survival with endocrine therapy for hormone receptor-positive, HER2-negative advanced breast cancer: review
We reviewed randomized phase II/III trials comparing first- or second-line endocrine therapy as monotherapy or in combination with targeted therapies for treatment of postmenopausal patients with hormone receptor-positive advanced breast cancer. First-line was defined as treatment for endocrine therapy-naïve advanced breast cancer or advanced disease treated with endocrine therapy in the adjuva...
متن کاملSevere gastrointestinal hemorrhage during targeted therapy for advanced breast carcinoma.
The introduction of targeted agents has improved survival for patients with a number of types of cancer, including several breast cancer subtypes. However, these agents are not without toxicities, and the fact that many patients are now on targeted therapy for extended periods of time has presented new challenges for the management of adverse effects. Everolimus is an inhibitor of mtor (the mam...
متن کاملEverolimus Plus Exemestane for the Treatment of Advanced Breast Cancer: A Review of Subanalyses from BOLERO-21
Hormone receptor-positive breast cancer is typically managed with endocrine therapies. However, resistance to endocrine therapy results in disease progression in a large proportion of breast cancers. Through the understanding of the mechanisms of endocrine resistance, identification of implicated pathways and targets has led to the development of novel agents targeting these pathways. Phosphoin...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
عنوان ژورنال:
- Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research
دوره 18 7 شماره
صفحات -
تاریخ انتشار 2015